Author

P. Majer

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Immunology· 1 Pharmacology & Toxicology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Organism:mouse· 2 Research Focus:cancer & tumor microenvironment· 1 Research Focus:drug response / drug discovery· 1 Organism:human· 1 Assay:imaging· 1

Frequent Co-Authors

B. S. Slusher· 2 shared R. Rais· 2 shared A. Amor-Coarasa· 1 shared A. J. Tam· 1 shared A. Nikolopoulou· 1 shared C. H. Patel· 1 shared C. Kratochwil· 1 shared D. Abou· 1 shared

Activity by Year

2019-2019 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 33 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersImmunology

B. S. Slusher

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Targeting glutamine metabolism enhances tumor specific immunity by inhibiting the generation of MDSCs and reprogramming tumor associated macrophages

M.-H. Oh, I.-H. Sun, L. Zhao, R. Leone, I.-M. Sun, W. Xu, S. L. Collins, A. J. Tam, R. L. Blosser, C. H. Patel, J. Englert, M. L. Arwood, J. Wen, Y. Chan-Li, P. Majer, , J. D. Powell

This study shows that targeting glutamine metabolism in tumors reduces MDSC generation, increases inflammatory macrophages, and enhances anti-tumor immunity, making checkpoint-resistant tumors responsive to immunotherapy.

bioRxiv · Jun 3, 2019 · PreprintImmunology

JHU-2545 Selectively Shields Salivary Glands and Kidneys during PSMA-Targeted Radiotherapy

M. T. Nedelcovych, R. P. Dash, Y. Wu, E. Y. Choi, R. S. Lapidus, P. Majer, D. Abou, M.-F. Penet, A. Nikolopoulou, A. Amor-Coarasa, J. Babich, D. L. Thorek, R. Rais, C. Kratochwil, B. S. Slusher

This paper describes the development of JHU-2545, a prodrug that selectively shields salivary glands and kidneys from PSMA-targeted radiotherapy, improving safety without affecting tumor uptake.

bioRxiv · Feb 15, 2019 · PreprintPharmacology & Toxicology